← All trials
NCT05806918
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2023
- Primary completion
- Jul 30, 2023
- Completion date
- Aug 30, 2023
- First posted
- Apr 10, 2023
- Last posted
- Apr 10, 2023
- Enrollment
- 368
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Lee's PharmaceuticalLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.